Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third of which is due by 2027.Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb (NYSE:BLCO), the Financial Times reported.
股權投資公司 TPG 和黑石正在聯手競購眼科公司 Bausch + Lomb（紐交所：BLCO），據《金融時報》報道。
Last month, Bausch + Lomb said it was considering a sale.
上個月，Bausch + Lomb 表示正在考慮出售。
The auction is part of an effort to address concerns from creditors, including Apollo Global Management Inc (NYSE:APO), over the separation from parent company, Bausch Health Companies (NYSE:BHC)..
此次拍賣是爲了解決債權人的擔憂，包括阿波羅全球管理公司（紐交所：APO），對與母公司Bausch Health Companies（紐交所：BHC）分離的問題。
The Bausch + Lomb spin-off was part of Bausch Health's plan to alleviate its $21 billion debt, a third of which is due by 2027.
Bausch + Lomb的分拆是Bausch Health計劃緩解210億美元債務的一部分，其中三分之一將於2027年到期。
If TPG and Blackstone are successful, the deal could rank among the largest private equity buyouts of the year. Bausch + Lomb's enterprise value, including debt, amounts to $11.5 billion.
如果 TPG 和黑石取得成功，該交易可能成爲全年最大的股權收購之一。Bausch + Lomb的企業價值，包括債務，達到115億美元。
Other potential bidders are no longer in the running, positioning TPG and Blackstone as the front-runners.
其他潛在投標者不再參與競購，將 TPG 和黑石置於領先地位。
The acquisition process is expected to value Bausch + Lomb at $13 billion to $14 billion, translating to a per-share price of up to $25.
預計收購過程將使Bausch + Lomb的估值達到130億至140億美元，對應每股價格高達25美元。
Goldman Sachs is leading the sale process to end a feud between Bausch Health's shareholders and creditors.
高盛正在主導銷售過程，以結束Bausch Health的股東和債權人之間的糾紛。
Bausch + Lomb CEO Brent Saunders orchestrated Allergan's $63 billion sale to AbbVie Inc (NYSE:ABBV). Formal bids are expected by the end of the month, though no deal is guaranteed.
bausch health首席執行官布倫特·桑德斯策劃了雅培公司（NYSE: ABBV）對安聯的630億美元出售。 預計本月底將出現正式買盤，儘管交易並不保證。
Bausch Health's top shareholders, including Carl Icahn and John Paulson's Paulson & Co., had supported the spin-off, seeing potential benefits in owning a larger share of the more profitable eye care subsidiary.
包括卡爾·伊坎和約翰·保爾森的保爾森與公司在內的Bausch Health的主要股東支持這一分拆，認爲擁有更具盈利能力的眼科子公司的更大股份能帶來潛在的好處。
Bausch Health currently faces challenges with its leading drug, Xifaxan, which will lose patent protection by 2029.
bausch health 目前面臨其主導藥品Xifaxan在2029年之前失去專利保護的挑戰。
Price Action: Bausch + Lomb stock is up 10.7% at $21.55 during the premarket session at last check Monday.
股價走勢：bausch health股價在週一最後一次查看的盤前交易中上漲10.7%，報21.55美元。
- GM Strikes Deal With Barclays To Supercharge Its Rewards Mastercard Program.
- 通用汽車與巴克萊銀行達成協議，以提升其獎勵萬事達信用卡計劃。
Image: Shutterstock
圖片：shutterstock
譯文內容由第三人軟體翻譯。
